Ticker Details
Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
IPO Date:	May 1, 2012
Sector:	Healthcare
Industry:	Drug Manufacturers
Market Cap:	$2.97B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.48 | 1.98%
Avg Daily Range (30 D):	$0.59 | 1.16%
Avg Daily Range (90 D):	$0.62 | 1.23%

Institutional Daily Volume
Avg Daily Volume:	.48M
Avg Daily Volume (30 D):	.46M
Avg Daily Volume (90 D):	.51M

Trade Size
Avg Trade Size (Sh.):	86
Avg Trade Size (Sh.) (30 D):	46
Avg Trade Size (Sh.) (90 D):	48

Institutional Trades
Total Institutional Trades:	4,723
Avg Institutional Trade:	$1.82M
Avg Institutional Trade (30 D):	$3.57M
Avg Institutional Trade (90 D):	$3.49M
Avg Institutional Trade Volume:	.06M
Avg Institutional Trades (Per Day):	1

Market Closing Trades
Avg Closing Trade:	$2.22M
Avg Closing Trade (30 D):	$5.75M
Avg Closing Trade (90 D):	$5.79M
Avg Closing Volume:	67.69K

News

Feb 23, 2026 @ 11:15 PM Supernus Pharmaceuticals to Participate in March I... Source: Na

Dec 16, 2025 @ 4:35 AM Supernus Stock Is Up 31% This Past Year but Still ... Source: Jonathan Ponciano

Jul 28, 2025 @ 12:25 PM Supernus Pharmaceuticals Announces Expiration of H... Source: Globe Newswire

Feb 11, 2025 @ 9:30 PM Supernus Pharmaceuticals to Host Conference Call a... Source: N/A

Nov 26, 2024 @ 10:00 PM Supernus to Participate in the 36th Annual Piper S... Source: N/A

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$-.68	$-.07	$-.68
Diluted EPS	$-.68	$-.07	$-.68
Revenue	$718.95M	$211.57M	$718.95M
Gross Profit	$644.39M	$188.57M	$644.39M
Net Income / Loss	$-38.55M	$-4.11M	$-38.55M
Operating Income / Loss	$-62.28M	$-3.94M	$-62.28M
Cost of Revenue	$74.56M	$23.01M	$74.56M
Net Cash Flow	$60.57M	$-22.92M	$60.57M
PE Ratio